Breast cancer, known for its diverse subtypes, ranks as one of the leading causes of cancer-related deaths.This study aimed to evaluate PSMA expression in breast cancer subtypes: luminal A, luminal B, HER2-pos., and tripleneg. breast cancer (TNBC).The study included the anal. of the Ki67 proliferation index, estrogen receptor (ER) expression, progesterone receptor (PR) expression, and HER2 status in conjunction with PSMA expression.This retrospective study included 98 early-stage breast cancer cases. PSMA expression was examined in both tumor cells and tumorassocd. blood vessels.The anal. revealed PSMA expression in tumor-associated blood vessels in 88 cases and in tumor cells in 75 cases. Ki67 expression correlated pos. with PSMA expression in blood vessels (p < 0.0001, R Spearman 0.42) and tumor cells (p = 0.010, R Spearman 0.26).The estrogen and progesterone receptor expression correlated neg. with PSMA levels in blood vessels (p = 0.0053, R Spearman 0.26 and p = 0.00026, R Spearman 0.347, resp.).HER2 status did not significantly impact PSMA expression.Our study confirms the presence of PSMA expression in breast cancer cells, particularly in tumor-associated blood vessels.'The anal. reveals a correlation between higher PSMA expression and aggressiveness of breast cancer cells, suggesting its potential involvement in angiogenesis and the formation of metastases.These findings provide novel information that may have some future implications for breast cancer imaging and treatment strategies.Triple-neg. breast cancer, characterized by its poor prognosis, high aggressiveness and PSMA overexpression, could particularly benefit from innovative therapeutic approaches.